AKT1 and urothelial carcinoma: Considering that ALK genomic alterations are rare and probably without prognostic implications in urothelial carcinoma [37], crizotinib may show antitumor activity against cisplatin-naïve and cisplatin-resistant BC by inhibiting the c-Met/PI3K/Akt pathway rather than the ALK pathway.